COPENHAGEN, Denmark, June 7, 2010 (GLOBE NEWSWIRE) -- Summary: Data presented at ASCO from the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head & neck cancer who have failed platinum-based chemotherapy.
